Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis.
FTY720 mediates activation suppression and G(0)/G (1) cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model.
The role of Acinetobacter in the pathogenesis of multiple sclerosis examined by using Popper sequences.
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation.
[Physical rehabilitation in multiple sclerosis: general principles and high-tech approaches].
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases.
FDA Approves First Drug for Lou Gehrig's Disease
Retinal Axonal Loss Begins Early in the Course of Multiple Sclerosis and Is Similar between Progressive Phenotypes.
Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis.
Cutting Edge: TNF Receptor-Associated Factor 4 Restricts IL-17-Mediated Pathology and Signaling Processes.
Tumefactive MS lesions under fingolimod: A case report and literature review.
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
Neuromyelitis Optica With Onset in Childhood and Adolescence.
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
Historical Issues of Optic neuritis and Sensory Disorder in Persian Traditional Medicine.
Brain Region-specific Alterations in the Gene Expression of Cytokines, Immune Cell Markers and Cholinergic System Components During Peripheral Endotoxin-induced Inflammation.
Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring-reply.
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS
Novel 3D analysis of Claudin-5 reveals significant endothelial heterogeneity among CNS microvessels.
Topographical and Biological Evidence Revealed FTY720-Mediated Anergy-Polarization of Mouse Bone Marrow-Derived Dendritic Cells In Vitro.
Treatment of HIV and Risk of Multiple Sclerosis.
The Spectrum of Neuromyelitis Optica (NMO) in Childhood.
FTY720 Impairs Mucosal Immunity and Clearance of the Enteric Pathogen Citrobacter rodentium.
A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
The pill times 2: What every woman with multiple sclerosis should know.
Pages
« first
‹ previous
…
164
165
166
167
168
169
170
171
172
…
next ›
last »